Huadong Medicine

Global Weight Loss Drugs Markets Report 2023-2024 & 2029 - The Emergence of GLP-1 and GIP, Unmet Market Needs and Emerging Product Pipeline - ResearchAndMarkets.com

Retrieved on: 
금요일, 4월 26, 2024
Health, Fitness & Nutrition, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Online, Conditional sentence, Market, Semaglutide, Sale, Investment, Social media, Injection, Weight gain, Huadong Medicine, Safety, Risk, Plasma protein binding, CDC, Underweight, Alli, OTC, Overweight, Eli Lilly, GSK plc, Diabetes, Weight loss, Research, Liraglutide, USFDA, Appetite, Success, Roche, Obesity, Culture, Novo Nordisk, Distribution, Patient, Powder, Metabolism, Marketing, GIP, Cancer, COVID-19, Pharmacy, Growth, Prevalence, Pharmaceutical industry

The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.

Key Points: 
  • The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.
  • The global weight loss drugs market is expected to grow at a CAGR of 49.85% over the years 2024-2029.
  • The weight loss drugs market in the Asia Pacific is expected to grow significantly during the forecasted period.
  • Offline distribution channels, comprising brick-and-mortar pharmacies, clinics, and healthcare facilities, dominated the global weight loss drugs market in 2023.

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Retrieved on: 
목요일, 11월 2, 2023
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Novartis Institute for Tropical Diseases, Research, NSCLC, Acute myeloid leukemia, IMGN, Food, PIN, Biomedical Research, ImmunoGen, European Medicines Agency, Doctor of Philosophy, Medicine, Capital expenditure, New Drug Application, Takeda Pharmaceutical Company, Marketing, BPDCN, ESGO, US Foods, Azacitidine, European Society of Gynaecological Oncology, EMA, ORR, NDA, Safety, Cancer, György Enyedi (geographer), Patient, National Medical Products Administration, Eli Lilly and Company, MAA, Congress, Mirvetuximab soravtansine, Blastic plasmacytoid dendritic cell neoplasm, ASH, Growth, ADC, Spacecraft, FDA, NMPA, PROC, University Clinical Centre in Gdańsk, Society, Senior, Inc., Huadong Medicine, AML, PARP, Vaccine, Pharmaceutical industry, Dietary supplement, Takeda

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
  • We also continued to monitor the NSCLC cohort with IMGC936 and advanced dose escalation with IMGN151, our second-generation ADC targeting FRα.
  • Selling, general and administrative expenses were $37.7 million for the quarter ended September 30, 2023 compared to $33.6 million for the quarter ended September 30, 2022.
  • Capital expenditures were $1.6 million and $1.1 million for the first nine months of 2023 and 2022, respectively.

Greenberg Traurig Advises China's Huadong Medicine in Two Strategic Licensing Agreements

Retrieved on: 
수요일, 9월 13, 2023
LLP, MC2, Greenberg Traurig, Atopic dermatitis, Negotiation, Psoriasis, Medical Technology Group, Calcipotriol/betamethasone dipropionate, Therapy, Pharmaceutical industry, Huadong Medicine

NEW YORK, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Greenberg Traurig, LLP represented Huadong Medicine Co., a Chinese publicly traded pharmaceutical company, in negotiating two strategic licensing agreements to develop and commercialize market-leading medications in Greater China and Southeast Asia.

Key Points: 
  • Greenberg Traurig, LLP represented Huadong Medicine Co., a Chinese publicly traded pharmaceutical company, in negotiating two strategic licensing agreements to develop and commercialize market-leading medications in Greater China and Southeast Asia.
  • NEW YORK, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Greenberg Traurig, LLP represented Huadong Medicine Co., a Chinese publicly traded pharmaceutical company, in negotiating two strategic licensing agreements to develop and commercialize market-leading medications in Greater China and Southeast Asia.
  • Most recently, the firm advised Hangzhou Zhongmei Huadong Pharmaceutical, a subsidiary of Huadong Medicine, in negotiating a licensing agreement with MC2 Therapeutics to develop and market MC2's Wynzora cream for treating plaque psoriasis in adults in Greater China.
  • In late June, Greenberg Traurig attorneys advised Huadong in negotiating a licensing agreement with Arcutis Biotherapeutic for the development, manufacture, and commercialization of topical roflumilast in Greater China and Southeast Asia.

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

Retrieved on: 
목요일, 8월 10, 2023
PDE4, Atopic dermatitis, Scalp, Psoriasis, Collaboration, Huadong Medicine, Greater China

With Huadong’s deep dermatology and regional expertise, we are confident they are the ideal partner to develop and commercialize topical roflumilast for multiple dermatological indications in the Greater China and Southeast Asia markets,” said Frank Watanabe, President and Chief Executive Officer, Arcutis.

Key Points: 
  • With Huadong’s deep dermatology and regional expertise, we are confident they are the ideal partner to develop and commercialize topical roflumilast for multiple dermatological indications in the Greater China and Southeast Asia markets,” said Frank Watanabe, President and Chief Executive Officer, Arcutis.
  • We are honored to partner with Arcutis to bring topical roflumilast to the Greater China and Southeast Asia markets and continue to make an impact for those suffering from immune-mediated skin diseases,” said Liang Lu, Chairman and CEO of Huadong Medicine.
  • Huadong will be responsible for development, manufacturing, and commercialization of roflumilast cream 0.3% and other topical roflumilast presentations in Greater China and Southeast Asia with the oversight of a joint steering committee comprised of individuals from both companies.
  • The transaction is effective immediately upon the execution of the Collaboration and License Agreement.

ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results

Retrieved on: 
월요일, 7월 31, 2023
Health, General Health, Capital expenditure, ASH, Marketing, MOH, European Medicines Agency, Survival, American Society of Clinical Oncology, György Enyedi (geographer), ESGO, Congress, Huadong Medicine, Patient, National Medical Products Administration, Spacecraft, European Hematology Association, Research, University Clinical Centre in Gdańsk, Mirvetuximab soravtansine, EMA, ADC, FDA, NMPA, Cancer, NSCLC, Acute myeloid leukemia, PROC, Ministry, PIN, ImmunoGen, MAA, Ovarian cancer, ORR, European Society of Gynaecological Oncology, Clinical trial, ASCO, AML, Azacitidine, Annual general meeting, EHA, BPDCN, Society, Food, Medicine, Vaccine, Pharmaceutical industry, Mobile phone

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.
  • Research and development expenses were $50.1 million for the quarter ended June 30, 2023 compared to $51.4 million for the quarter ended June 30, 2022.
  • Selling, general and administrative expenses were $36.4 million for the quarter ended June 30, 2023 compared to $23.8 million for the quarter ended June 30, 2022.
  • Net loss for the second quarter of 2023 was $4.2 million, or $0.02 per share, compared to a net loss of $62.0 million, or $0.24 per share, for the second quarter of 2022.

Sanyou Forms Partnership with Hangzhou Zhongmei Huadong Pharmaceutical, Catalyzing Innovative Drug Research and Development

Retrieved on: 
수요일, 6월 28, 2023
R, Partnership, Investment, Patient, Medicine, Pharmaceutical industry, Fine chemical, Huadong Medicine

We have been enriching our pipeline layout of innovative drug R&D through a combination of independent R&D, collaborative and commissioned development, and pipeline license-in.

Key Points: 
  • We have been enriching our pipeline layout of innovative drug R&D through a combination of independent R&D, collaborative and commissioned development, and pipeline license-in.
  • "We are greatly honored to establish a further strategic partnership with Huadong Medicine," stated Dr. Guojun Lang, CEO of Sanyou.
  • The signing of this agreement signifies the milestone achievement in the development of this innovative drug candidate.
  • In the future, Sanyou will continue to exert our utmost efforts to support our partners in accelerating the innovative drug R&D process."

Global CAR T Cell Therapy Competitive Landscape Report 2023: Insights About 250+ Companies and 500+ Drug Profiles - Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
금요일, 5월 12, 2023
Health, Other Health, ASH, Therapy, Multiple myeloma, Cell therapy, New Drug Application, Roche, Clinical trial, NDA, Research, American Society of Hematology, Competition, Report, ORR, Huadong Medicine, Lymphoma, Acquisition, Patient, National Medical Products Administration, Annual general meeting, Cell, Mergers and acquisitions, Poster, Safety, NMPA, Society, Medicine, Pharmaceutical industry, Hematology

This report provides comprehensive insights about 250+ companies and 500+ drugs in CAR T - Cell Therapy Competitive landscape.

Key Points: 
  • This report provides comprehensive insights about 250+ companies and 500+ drugs in CAR T - Cell Therapy Competitive landscape.
  • It covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends.
  • The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

Retrieved on: 
금요일, 4월 28, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Biologics license application, Capital expenditure, Society, SGO, ASH, Senior, Progression-free survival, Marketing, European Medicines Agency, Survival, Clinical trial, Cancer, Gynecologic Oncology (journal), György Enyedi (geographer), Society of Gynecologic Oncology, NSCLC, Lung cancer, PFS, Mirvetuximab soravtansine, Gilead, Eli Lilly, EMA, Acute myeloid leukemia, PROC, AML, Azacitidine, PIN, Huadong Medicine, Pharmakon—Danish College of Pharmacy Practice, Patient, National Medical Products Administration, Annual general meeting, ImmunoGen, Vertex Pharmaceuticals, ADC, Spacecraft, MAA, Research, FDA, Ovarian cancer, LP, BLA, NMPA, Medicine, Vaccine, Management, Pharmaceutical industry, Mobile phone, Vertex

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
  • Research and development expenses rose to $51.6 million for the quarter ended March 31, 2023 compared to $44.3 million for the quarter ended March 31, 2022.
  • Selling, general and administrative expenses were $40.0 million for the quarter ended March 31, 2023 compared to $16.6 million for the quarter ended March 31, 2022.
  • ImmunoGen had $201.2 million in cash and cash equivalents as of March 31, 2023, compared with $275.1 million as of December 31, 2022.

$12.2 Billion Worldwide Facial Injectables Industry to 2027 - Featuring Allergan, Anika Therapeutics, Galderma Pharma and Sanofi Among Others - ResearchAndMarkets.com

Retrieved on: 
화요일, 10월 11, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Social media, Skin, Traction, Pharma, Elasticity, Industry, Collagen, COVID-19, Face, Huadong Medicine, Hyaluronic acid, Tissue paper

Facial injectables are administered on specific areas of the face to enhance the physical appearance of the skin.

Key Points: 
  • Facial injectables are administered on specific areas of the face to enhance the physical appearance of the skin.
  • Currently, facial injectables are gaining traction worldwide as they are safe, cost-effective and require minimal downtime.
  • What are the major regions in the global facial injectables market?
  • 9. Who are the key companies/players in the global facial injectables market?

DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022

Retrieved on: 
화요일, 7월 12, 2022
Income, BCMA, Achievement, AACR, Safety, August Faller GmbH & Co. KG, Federal Ministry of Finance (Germany), Federal Ministry for Economic Affairs and Energy, FSE, Spanish mythology, Telix, Federal Financial Supervisory Authority, Therapy, American Association, ADC, Patient, CEO, Phase, Medicine, Economy, COVID-19, Kidney, Redhill, Multiple myeloma, Federal, Huadong Medicine, HPHA, CFO, Lymphatic system, Depreciation, Association, Gesellschaft mit beschränkter Haftung, Annual general meeting, Partnership, NASDAQ, Security (finance), Fine chemical, Pharmaceutical industry

Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: "We are looking back on an exceptionally successful first half of the year.

Key Points: 
  • Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: "We are looking back on an exceptionally successful first half of the year.
  • The Heidelberg Pharma Group (Heidelberg Pharma) comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH reports consolidated figures.
  • The net loss posted by the Heidelberg Pharma Group for the first six months of 2022 came to EUR8.6 million (previous year: EUR13.1 million).
  • In this respect, the full-year financial guidance issued on 24 March 2022 for the Heidelberg Pharma Group will not be adjusted at this time.